1.
|
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Approved-not yet active
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCCTG-N1087, N1087, NCT01369849
|
|
2.
|
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: MDA-2010-0247, 2010-0247, 8727, NCT01239342
|
|
3.
|
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: CHNMC-PHII-105, PHII-105, 8752, NCT01239355
|
|
4.
|
Phase: Phase II
Type: Treatment
Status: Active
Age: Adult
Sponsor: NCI
Protocol IDs: SWOG-S1005, S1005, NCT01260701
|
|
5.
|
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: ECOG-E2809, E2809, NCT01251861
|
|
6.
|
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Approved-not yet active
Age: 18 and over
Sponsor: NCI
Protocol IDs: MDA-2010-0261, 2010-0261, 8728
|
|
7.
|
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: 2009-0360, P01 CA148133, NCT01248247
|
|
8.
|
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 to 65
Sponsor: NCI, Other
Protocol IDs: 2010-0242, NCT01277757
|
|
9.
|
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 10-402, NCT01283035
|
|
10.
|
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: CHNMC-PHII-108, PHII-108, 8698, NCT01294306
|
|
11.
|
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: 2010-0243, NCT01253447
|
|
12.
|
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: DFCI-10258, 10.258, 8760, NCT01307631
|
|
13.
|
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: AECM-AAAF3912, AAAF3912, 8740, NCT01319539
|
|
14.
|
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: MAYO-MC1079, MC1079, 8761, NCT01349933
|
|
15.
|
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: 110096, 11-C-0096, NCT01306045
|
|
16.
|
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: OSU-10104, OSU-10104, 8735, NCT01425879
|
|
17.
|
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: 110117, 11-C-0117, NCT01333475
|
|
18.
|
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: LEONB-ET-2011-041, ET-2011-041, 9022, NCT01481129
|
|
19.
|
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 to 90
Sponsor: Other
Protocol IDs: AKTIL, NCT01466868
|
|
20.
|
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: MCC-VICCMEL1120, VICCMEL1120, 8867, NCT01519427
|
|
21.
|
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: CALGB-A091104, A091104, NCT01604772
|
|
22.
|
Phase: Phase II
Type: Tissue collection/Repository, Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: SWOG-S1115, S1115, NCT01658943
|
|
23.
|
Phase: Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: 2206-010, 2009_698, NCT01021748
|
|
24.
|
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 20 and over
Sponsor: Other
Protocol IDs: 201001017M, NCT01147211
|
|
25.
|
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 1 to 21
Sponsor: NCI
Protocol IDs: COG-ADVL1013, ADVL1013, ADVL1013, NCT01231919
|
Mobile | Español
